The Kalamazoo, Mich.-based company developed and produces the Peregrine infusion ablation catheter for treating hypertension. The Peregrine system infuses neurolytic agents into the perivascular space surrounding the renal artery to ablate the sympathetic nerves that contribute to hypertension.
The money comes from 24 unnamed investors, according to the SEC Filing. Ablative Solutions has not commented as to what the funds from the round will be used for.
In May, Ablative Solutions said it received CE Mark approval in the European Union for its Peregrine infusion ablation catheter for treating uncontrolled hypertension. The company began testing Peregrine last year in Poland.
Ablative Solutions said it’s enrolling patients in a clinical trial for the treatment in Europe. The company said it also plans to initiate a post-market study to gather additional clinical data on the treatment.
In the U.S., the company has received 510(k) clearance from the FDA as a “tool for the infusion of diagnostic and therapeutic agents into the perivascular area of a peripheral vasculature,” Ablative Solutions said. The company said it’s still in the planning stage for a U.S. clinical trial for the hypertension indication.